Cabergoline - Open Access .click

Results 31 to 40 of about 3,840 (115)

Advancements in Molecular Diagnosis and Pharmacotherapeutic Strategies for Invasive Pituitary Adenomas

Immunity, Inflammation and Disease, Volume 12, Issue 12, December 2024.
ABSTRACT Background The overwhelming majority of pituitary tumors consist of pituitary adenomas (PAs), which have recently also been termed pituitary neuroendocrine tumors (PitNETs). Clinically significant PAs occur in approximately one in every 1000 individuals, while other types of pituitary tumors, such as craniopharyngiomas and pituicytomas, are ...
Dingkai Xu, Ling Wang, Maohua Zheng
wiley +1 more source

Tools for clinical pharmacists to identify medications that can cause drug‐induced cognitive impairment: A systematic review

JACCP: JOURNAL OF THE AMERICAN COLLEGE OF CLINICAL PHARMACY, Volume 7, Issue 12, Page 1207-1227, December 2024.
Abstract Cognitive impairment affects around 19% of community‐dwelling older adults in the United States. Pharmacists can play a significant role in identifying and deprescribing cognitive‐impairing medications through cognitive‐focused medication reviews or as part of comprehensive medication management.
Jacob Stanton +4 more
wiley +1 more source

CABERGOLINE IN PRACTICAL MAMMOLOGY

Medical Council, 2016
Abnormal increase in prolactin hyperprolactinemia is one of the main signs of hypothalamic-pituitary-ovarian dysfunction. Consequently, the effect of dopamine on lactophores is attenuated resulting in their persistent hyperplasia and formation of functionally active microand macro-adenomas followed by an even greater prolactin level increase. According
I. V. Vysotskaya, T. Depuis, V. P. Letyagin +2 more
openaire +3 more sources

Cabergolin